查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466293

重組蛋白市場：按產品、服務、最終用戶、功能分類 - 全球預測 2024-2030

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年重組蛋白市場規模為50.5億美元，預計2024年將達58億美元，2030年將達130.4億美元，複合年成長率為14.51%。

重組蛋白是透過將修飾的基因插入細菌、酵母或哺乳動物細胞等表現系統中來產生的，以產生具有高純度和功能性的所需蛋白。 Recombinant Proteins 從事源自重組 DNA 技術的基因工程蛋白質的研究、開發、製造和商業化。由於感染疾病和慢性病的流行、新療法和診斷方法的醫療支出增加以及生物製藥公司研發投資的增加，對高品質重組蛋白的需求不斷增加。基因組學技術的快速進步以及生技藥品相對於小分子藥物的日益採用正在推動重組蛋白的採用不斷增加。然而，高昂的生產和維護成本可能會對最終用途產業使用重組 DNA 產生負面影響。此外，動物育種和飼料效率的新應用以及重組蛋白開發的大量投資預計將推動全球最終用途部門使用這些蛋白質。

主要市場統計
基準年[2023] 50.5億美元
預測年份 [2024] 58億美元
預測年份 [2030] 130.4億美元
複合年成長率（%） 14.51%

黏附分子和受體在產品研究中的重要用途

黏附分子和受體對於細胞間通訊、遷移和免疫反應調節至關重要。這些被廣泛用於了解癌症、發炎和感染疾病的研究。生長因子和趨化素控制細胞生長、分化和遷移過程。這些對於創傷治療、組織修復和幹細胞研究的應用至關重要。免疫反應蛋白是控制感染防禦機制和發炎控制的免疫系統的重要組成部分。研究人員使用免疫反應蛋白來研究自體免疫疾病和疫苗開發。激酶蛋白在控制細胞分裂、生存、代謝和其他生物過程的細胞內訊號傳導途徑中至關重要。激酶蛋白作為癌症治療和慢性發炎治療的藥物標靶具有重要的潛力。膜蛋白在細胞訊號傳導、運輸和黏附中很重要，並參與許多生理過程，這導致它們在藥物發現和開發中的應用。重組代謝酶在調節細胞代謝和能量產生的生物途徑中至關重要。這些用於針對糖尿病和肥胖症等代謝疾病的藥物發現。調節蛋白控制基因表現和細胞過程，例如細胞凋亡和細胞週期進程。這些蛋白質廣泛用於癌症治療和其他涉及不受控制的細胞增殖和分化的疾病。結構蛋白為細胞和組織提供機械支撐，同時保持生物體內的結構完整性。它應用於組織工程和再生醫學相關的生物醫學研究。

服務 表達服務注重高產量和與目標蛋白質特性的兼容性。

重組蛋白的克隆涉及將目標基因插入適當的表達載體，產生指導宿主細胞中蛋白質生產的重組DNA分子。基於需求的克隆服務偏好包括高效率、特異性和對不同生物的適應性。表達是指將遺傳訊息轉化為功能性蛋白質產物的過程。有幾個因素會影響表現系統的選擇，包括生產力水平、與轉譯後修飾(PTM) 的兼容性以及下游應用所需的更高產量和純度水平的放大難度。精製對於去除表達蛋白中的污染物以用於藥物發現、診斷和研究等下游應用至關重要。對精製服務的需求包括高選擇性、重現性、產量和最小的樣品損失。隨著分子生物學技術的進步使得同時創建多個克隆成為可能，對克隆服務的需求不斷增加。表達服務透過宿主系統的改進而不斷發展，以適應不同複雜程度的多種蛋白質。隨著樹脂化學和設備的進步，精製服務不斷進步，從而實現更高的產量和產量。

最終用戶：重組蛋白在製藥和生物製藥公司的廣泛使用

學術研究機構是重組蛋白技術創新和高級研究的基礎。這些實驗室需要高品質、可靠且具成本效益的重組蛋白來進行結構生物學、功能研究、藥物發現和診斷研究。受託製造廠商（CMO）和合約研發組織（CRO）為專門從事重組蛋白生產、分析開發和臨床前測試的生物製藥公司提供研發和產品開發外包服務。這些公司強調快速交付、有競爭力的價格和可客製化的服務，以滿足客戶的需求。生物製藥公司需要高品質、符合 GMP 的重組蛋白來開發治療和診斷方法。這些最終用戶群體優先考慮品質、可靠性和經濟高效的解決方案。此外，CRO 和 CMO 優先考慮滿足截止日期和多樣化客戶的客製化產品，而製藥和生物製藥公司則需要嚴格的監管合規性和強大的製造能力。

功能：重組蛋白在藥物發現和藥物開發的潛在需求

重組蛋白對於診斷至關重要，有助於各種疾病的檢測和監測。酵素結合免疫吸附檢測法（ELISA）或側流免疫檢測是一種常見的診斷技術，利用重組蛋白作為抗原或抗體來檢測與特定疾病相關的特定生物標記。重組蛋白在生技藥品、疫苗、細胞和基因療法的藥物發現和製造中發揮重要作用，並作為潛在的治療標靶和候選藥物。此外，它還有助於進行高通量篩檢測定，以識別針對特定疾病途徑的先導化合物。診斷應用主要關注靈敏度、特異性、快速性和成本效益。相較之下，藥物發現和開發強調重組蛋白的純度、穩定性、擴充性和功能活性。

區域洞察

由於美洲擁有成熟的製藥和生物技術公司，擁有先進的研究設施和確保高品質產品的法規，重組蛋白市場正在不斷發展。此外，技術的進步、研發 (R&D) 資金的大幅增加、慢性病盛行率的上升以及對個人化藥物的需求不斷成長正在推動美洲對重組蛋白的需求。歐洲、中東和非洲地區是重組蛋白市場的新興市場，因為對這些蛋白的使用有嚴格的規定，而且製造商必須遵守 GMP 標準。由於慢性病的流行、細胞生物學、生物化學、結構和生物物理研究活動的增加以及對高效生物製藥的需求，亞太地區的重組蛋白市場正在不斷成長。此外，生物製藥公司和學術機構之間的技術進步和合作正在加速將實驗室創新轉化為商業性可行的產品，並且預計將促進世界各地最終用途部門對重組蛋白的採用。

FPNV定位矩陣

FPNV定位矩陣對於評估重組蛋白市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對重組蛋白市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1、重組蛋白市場規模及預測如何？

2.重組蛋白市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3. 重組蛋白市場的技術趨勢和法規結構是什麼？

4.重組蛋白市場主要廠商的市場佔有率為何？

5. 進入重組蛋白市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 消費者越來越重視個人化醫療和蛋白質療法
      • 老年人和兒童感染疾病和慢性病盛行率高
      • 生物製藥和生物相似藥蛋白的需求快速成長
    • 抑制因素
      • 重組蛋白成本與維護時間問題
    • 機會
      • 對生物標記發現的更多關注和對重組蛋白開發的投資激增
      • 重組蛋白在動物繁殖、飼料效率和健康方面的潛力不斷成長
    • 任務
      • 替代產品的可用性和一些生產問題
  • 市場區隔分析
    • 產品：黏附分子和受體在研究中的重要用途
    • 服務：表達服務注重高產量和與目標蛋白質特性的兼容性
    • 最終用戶：重組蛋白在製藥和生物製藥公司的廣泛使用
    • 功能：重組蛋白在藥物發現與開發的潛在需求
  • 市場趨勢分析
    • 研究成本不斷增加，整個美洲的醫療基礎設施也不斷增加。
    • 亞太地區慢性病盛行率和醫學研究的重大投資
    • 擴大歐洲、中東和非洲地區藥品生產設施和重組蛋白的監管指南。
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章重組蛋白市場：依產品

  • 黏附分子和受體
  • 生長因子和趨化素
  • 免疫反應蛋白
  • 激酶蛋白
  • 膜蛋白
  • 重組代謝酶
  • 調節蛋白
  • 結構蛋白

第7章重組蛋白市場：依服務分類

  • 複製
  • 表達
  • 精製

第 8 章重組蛋白市場：依最終用戶分類

  • 學術研究所
  • 合約研究組織和合約製造組織
  • 製藥和生物製藥公司

第 9 章重組蛋白市場：按功能

  • 診斷
  • 藥物發現與開發

第10章美洲重組蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太重組蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲重組蛋白市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • iTolerance 與 Northway Biotech 簽署融合蛋白生產協議
    • Biovian 在芬蘭製造工廠投資超過 5,000 萬歐元
    • 富通生命科學公司收購 International Point of Care
    • Curia 利用 CHOZN 平台擴展細胞株開發服務
    • Future Fields 融資 1,120 萬美元，擴大果蠅重組蛋白生產規模
    • 默克生物開發中心擴建，法國馬蒂利亞克
    • Shenandoah Biotechnology 宣布擴大根據 cGMP 實踐生產的 CTGrade 重組蛋白系列
    • FUJIFILM收購領先的重組蛋白製造商 Shenandoah Biotechnology
    • Thermo Fisher Scientific 完成對 Peprotech 的收購，進軍重組蛋白領域

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-501246437434

[187 Pages Report] The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023 and expected to reach USD 5.80 billion in 2024, at a CAGR 14.51% to reach USD 13.04 billion by 2030.

The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 5.05 billion
Estimated Year [2024] USD 5.80 billion
Forecast Year [2030] USD 13.04 billion
CAGR (%) 14.51%

Product: Significant use of adhesion molecules & receptors for research purposes

Adhesion molecules and receptors are essential for cell-cell communication, migration, and immune response regulation. They are widely used in research to understand cancer, inflammation, and infection. Growth factors and chemokines regulate cellular growth, differentiation, and migration processes. They are vital for wound healing, tissue repair, and stem cell research applications. Immune response proteins are crucial components of the immune system that regulate infection defense mechanisms and inflammation control. Researchers use the immune response proteins to study autoimmune diseases and vaccine development. Kinase proteins are essential in cellular signal transduction pathways regulating cell division, survival, metabolism, and other biological processes. Kinase proteins possess significant potential as drug targets for cancer treatment and management of chronic inflammatory conditions. Membrane proteins are crucial for cell signaling, transport, and adhesion and have applications in drug discovery and development due to their involvement in numerous physiological processes. Recombinant metabolic enzymes are vital in biological pathways regulating cellular metabolism and energy production. They are used in drug discovery efforts targeting metabolic diseases, such as diabetes or obesity. Regulatory proteins control gene expression or cellular processes such as apoptosis and cell cycle progression. They are extensively used for cancer treatment and other diseases involving uncontrolled cell growth or differentiation. Structural proteins provide mechanical support to cells and tissues while maintaining structural integrity within organisms. They find applications in biomedical research related to tissue engineering or regenerative medicine.

Services: Expression services focus on high yields and compatibility with target protein characteristics

Recombinant protein cloning involves the insertion of a target gene into an appropriate expression vector, resulting in a recombinant DNA molecule that directs protein production in host cells. Need-based preferences for cloning services include high efficiency, specificity, and adaptability to different organisms. Expression refers to the process of translating a gene's information into a functional protein product. Several factors influence the choice of an expression system, such as productivity levels, compatibility with post-translational modifications (PTMs), and ease of scale-up for higher yields or purity levels required for downstream applications. Purification is essential to remove contaminants from the expressed protein and prepare it for downstream applications such as drug discovery, diagnostics, and research. Preferences for purification services include high selectivity, reproducibility, yield, and minimal sample loss. The demand for cloning services has increased due to advancements in molecular biology techniques, enabling the generation of multiple clones simultaneously. Expression services have evolved with improvements in host systems to accommodate diverse proteins with varying complexity levels. Purification services continue progressing with resin chemistry and instrumentation advances, allowing higher throughput and yields.

End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies

Academic research institutes are the foundation for innovative and advanced research in recombinant protein technology. These institutes require high-quality, reliable, cost-effective recombinant proteins to study structural biology, functional studies, drug discovery, and diagnostics. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) provide outsourced research and product development services to biopharmaceutical companies specializing in recombinant protein production, assay development, and preclinical testing. They value rapid turnaround times, competitive pricing structures, and customizable offerings tailored to their customer needs. Pharmaceutical biopharmaceutical companies require high-quality, GMP-compliant recombinant proteins for therapeutic and diagnostic product development. These end-user segments prioritize quality, reliability, and cost-effective solutions. Academic research institutes emphasize discovery-driven research application support; biotechnology companies value customization and scalability; CROs and CMOs prioritize turnaround time and customized offerings catering to diverse customers, while pharmaceutical and biopharmaceutical companies require robust manufacturing capabilities with strict regulatory compliance.

Function: Potential demand of recombinant proteins for drug discovery & development

Recombinant proteins are essential in diagnostics, facilitating detection and monitoring of various diseases. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunoassays are common diagnostic techniques that utilize recombinant proteins as antigens or antibodies to detect specific biomarkers associated with specific diseases. Recombinant proteins play an indispensable role in drug discovery and production of biologics, vaccines, and cell and gene therapies and serve as potential therapeutic targets or drug candidates themselves. Additionally, they facilitate high throughput screening assays to identify lead compounds targeting specific disease pathways. Diagnostic applications primarily focus on sensitivity, specificity, rapidness, and cost-effectiveness. In contrast, drug discovery & development emphasizes recombinant proteins' purity, stability, scalability, and functional activity.

Regional Insights

The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Recombinant Proteins Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins
  • Services
    • Cloning
    • Expression
    • Purification
  • End-User
    • Academic Research Institutes
    • Contract Research Organizations & Contract Manufacturing Organizations
    • Pharmaceutical & Biopharmaceutical Companies
  • Function
    • Diagnostics
    • Drug Discovery & Development
      • Biologics
      • Cell & Gene Therapy
      • Vaccines
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Recombinant Proteins Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Recombinant Proteins Market?

3. What are the technology trends and regulatory frameworks in the Recombinant Proteins Market?

4. What is the market share of the leading vendors in the Recombinant Proteins Market?

5. Which modes and strategic moves are suitable for entering the Recombinant Proteins Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
      • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
      • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
      • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative products and several issues in production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
    • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
    • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
    • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
  • 5.3. Market Trend Analysis
    • 5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
    • 5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
    • 5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Recombinant Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. Adhesion Molecules & Receptors
  • 6.3. Growth Factors & Chemokines
  • 6.4. Immune Response Proteins
  • 6.5. Kinase Proteins
  • 6.6. Membrane Proteins
  • 6.7. Recombinant Metabolic Enzymes
  • 6.8. Regulatory Proteins
  • 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

  • 7.1. Introduction
  • 7.2. Cloning
  • 7.3. Expression
  • 7.4. Purification

8. Recombinant Proteins Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development

10. Americas Recombinant Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
    • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
    • 13.3.3. Fortis Life Sciences acquires International Point of Care
    • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
    • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
    • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
    • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
    • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
    • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
  • FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS RECOMBINANT PROTEINS M